VIRTICI LLC
Bispecific antibody (VTC-890) that binds LIGHT and TL1A cytokines to treat idiopathic pulmonary fibrosis
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Total capital
- $27.4M
- Federal grants
- $26.2M
- 53 awards · 2015–2026
- Rank in peer group#119 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $1.2M
- 2 awards · Health and Human S
- Rank in Biotech#177 of 4373
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$904K
- Federal grantHealth and Human S · Phase I · A Novel Anti-infective Therapy for Treating Periodontitis$309K
- Federal grantHealth and Human S · Phase II · A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection$699K
- Federal grantHealth and Human S · Phase II · A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$1.0M
- Federal grantHealth and Human S · Phase II · A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection$924K
- Federal grantHealth and Human S · Phase I · A Novel Blood Test for Early Diagnosis of Frontotemporal Lobar Degeneration$700K
- Federal grantHealth and Human S · Phase II · A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$1M
Show 47 earlier federal awards
- Federal grantHealth and Human S · Phase I · A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection$307K
- Federal grantHealth and Human S · Phase I · A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$257K
- Federal grantHealth and Human S · Phase I · A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$281K
- Federal grantHealth and Human S · Phase I · A Novel Small Molecule for the Treatment of Periodontitis$306K
- Federal grantHealth and Human S · Phase II · A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$979K
- Federal grantHealth and Human S · Phase I · A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection$307K
- Federal grantHealth and Human S · Phase I · A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$216K
- Federal grantHealth and Human S · Phase II · A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$306K
- Federal grantHealth and Human S · Phase I · A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$441K
- Federal grantHealth and Human S · Phase I · A Novel Small Molecule for the Treatment of Periodontitis$306K
- Federal grantHealth and Human S · Phase I · A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$73K
- Federal grantHealth and Human S · Phase I · A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$292K
- Federal grantHealth and Human S · Phase II · A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$980K
- Federal grantHealth and Human S · Phase I · A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$613K
- Federal grantHealth and Human S · Phase I · A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$30K
- Federal grantHealth and Human S · Phase II · A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$306K
- Federal contractHealth and Human S · Development Of Toll-like Receptor Agonists To Strengthen Sublingual Vaccines.$600K
- Federal grantHealth and Human S · Phase I · A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$412K
- Federal grantHealth and Human S · Phase II · A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$994K
- Federal grantHealth and Human S · Phase I · A Novel LIGHT/TL1A Bispecific Antibody for the Treatment of Fibrotic Diseases$299K
- Federal grantHealth and Human S · Phase I · A Novel LIGHT/TL1A Bispecific Antibody for the Treatment of Fibrotic Diseases$299K
- Federal grantHealth and Human S · Phase I · A Novel Probiotic-Based Nanobody Delivery Platform$281K
- Federal grantHealth and Human S · Phase I · A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients$159K
- Federal grantHealth and Human S · Phase II · A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$300K
- Federal grantHealth and Human S · Phase I · A Novel Probiotic-Based Nanobody Delivery Platform$300K
- Federal grantHealth and Human S · Phase I · A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients$459K
- Federal grantHealth and Human S · Phase I · A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients$300K
- Federal contractHealth and Human S · Igf::ot::igf A Novel Adjuvant-based Probiotic Platform For Generating Tolerance Therapeutics$585K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance Therapeutic for Treating Graves' Disease$300K
- Federal grantHealth and Human S · Phase II · A Novel Tolerance Therapeutic for Treating Graves' Disease$300K
- Federal grantHealth and Human S · Phase II · A Novel Peptide Therapeutic for Obesity$829K
- Federal grantHealth and Human S · Phase II · A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$990K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance Therapeutic for Treating Type Diabetes$300K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance Therapeutic for Treating Type 1 Diabetes$300K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance inducing Probiotic Platform$300K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance-inducing Probiotic Platform$300K
- Federal grantHealth and Human S · Phase I · A Novel Probiotic for the Treatment of Rheumatoid Arthritis$225K
- Federal grantHealth and Human S · Phase II · A Novel Peptide Therapeutic for Obesity$1M
- Federal grantHealth and Human S · Phase II · A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$2M
- Federal grantHealth and Human S · Phase II · A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$1M
- Federal grantHealth and Human S · Phase I · A Novel Probiotic for the Treatment of Sjogren's Syndrome$225K
- Federal grantHealth and Human S · Phase I · A Novel Probiotic for the Treatment of Sjogren's Syndrome$225K
- Federal grantHealth and Human S · Phase II · A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$480K
- Federal grantHealth and Human S · Phase I · A Novel Therapeutic Peptide for Treating Stroke$434K
- Federal grantHealth and Human S · Phase I · A Novel Therapeutic Peptide for Treating Stroke$434K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance Therapeutic for Treating Peanut Allergy$319K
- Federal grantHealth and Human S · Phase I · A Novel Tolerance Therapeutic for Treating Peanut Allergy$319K
Federal awards are summed by year (54 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#119 · top 23%
- Linked publications#86 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 5- PendingTolerance Therapeutic For Treating Polypeptide Induced Immune ActivationUSPTOApplication 16077267
- PendingTolerance Therapeutic For Treating Polypeptide Induced AllergyUSPTOApplication 15550696
- PendingTolerance Therapeutic For Treating Polypeptide Induced Immune ActivationUSPTOApplication PCTUS2017017346
Show all 5 patent records
- Tolerance Therapeutic For Treating Polypeptide Induced Immune ActivationMar 7, 2019 · Application 16077267Pending
- Tolerance Therapeutic For Treating Polypeptide Induced AllergyAug 30, 2018 · Application 15550696Pending
- Tolerance Therapeutic For Treating Polypeptide Induced Immune ActivationApplication PCTUS2017017346Pending
- Tolerance Therapeutic For Treating Polypeptide Induced AllergyApplication PCTUS2016017877Pending
- Tolerance Therapeutic For Treating Polypeptide Induced Immune ActivationApplication 62294934Pending
Recent research by its founders
- Treatment with a Lactococcus lactis that chromosomally express E. coli cfaI mitigates salivary flow loss in a Sjögren’s syndrome-like disease20233 cites
- Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire202114 cites
- Modified High-Molecular-Weight Hyaluronan Promotes Allergen-Specific Immune Tolerance201632 cites
Related companies, and why
- APPLIED STEMCELL, INC.Similar federal contract value in Biotech · $1.2M in contracts
- Akron Biotechnology, LLCSimilar federal contract value in Biotech · $1.2M in contracts
- Ultima Genomics, Inc.Similar federal contract value in Biotech · $1.2M in contracts
- Htg Molecular Diagnostics, IncSimilar federal contract value in Biotech · $1.2M in contracts
- EXTEND BIOSCIENCES INCSimilar federal contract value in Biotech · $1.1M in contracts
- ORBIS BIOSCIENCES, INC.Similar federal contract value in Biotech · $1.1M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .